Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Compass Pathways PLC (CMPS) reports $433 million in cash and advances rolling NDA submission for COMP360 in treatment-resistant depression, targeting a first-half 2027 launch.
LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.
Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.
Annuity payouts are the most competitive they have been in years, which makes the timing of this comparison unusually consequential for anyone sitting on a $675,000 nest egg and trying to decide which structure actually puts more money in their pocket for life.
Johnson & Johnson (JNJ) is back in focus after longtime executive Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, with experienced biopharmaceutical leader Tom Cavanaugh set to succeed her. See our latest analysis for Johnson & Johnson. Johnson & Johnson’s share price has had a strong run in 2026, with a year to date share price return of 22.95% and a 90 day share price return of 13.49%, while the 1 year total shareholder return of 53.04%...
Replacing a six-figure salary with dividends is a math problem first, and the capital requirement swings by more than a million dollars depending on one variable most investors treat as an afterthought.
Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.
Goldman Sachs just handed Microsoft its most coveted endorsement while cutting three other tech giants loose, and the reasoning behind that trade reveals exactly where Wall Street thinks the AI money flows next.
GS, JPM, TRV and JNJ stand out as Dow hits a new high amid an AI-driven tech sell-off, with these blue-chip stocks backed by strong earnings growth.
Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.
Medicare quietly pockets a chunk of your Social Security before it ever reaches you, and the gap between what you expect and what you receive keeps widening every year. Three ETFs target that exact shortfall with income built to arrive on a schedule.
Johnson & Johnson (NYSE:JNJ) received FDA authorization for its OTTAVA robotic surgical system. The company is moving ahead with the commercial launch of OTTAVA as its first table integrated, soft tissue robotic platform. This marks Johnson & Johnson's entry into the competitive surgical robotics market with a differentiated system design. For investors watching Johnson & Johnson, the OTTAVA approval adds a new dimension to the MedTech story. Surgical robotics has become a focus area for...
Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money’s July 23 episode. After days of urging investors to accumulate the stock following a strong earnings report that Wall Street initially dismissed, Cramer highlighted the FDA approval of JNJ’s OTTAVA Robotic Surgical System as the catalyst that finally […]
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
J&J's oncology business posted strong Q2 growth as Darzalex, Erleada and newer cancer drugs boosted sales and advanced its long-term ambitions.
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Johnson & Johnson (NYSE:JNJ) outlined its commercialization plans for the OTTAVA robotic surgical system after receiving U.S. Food and Drug Administration De Novo authorization, positioning the table-integrated platform as a long-term growth initiative in surgical robotics. The company said it
Here is how Avantor, Inc. (AVTR) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.
The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Stock Market Today: The Dow Jones index rallied 600 points Monday after Trump called off new U.S. strikes on Iran. Oil prices plunged.
As stocks pull back from recent highs, lean into these three blue chip dividend stocks.
After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race years earlier, or is the market already spoken for?
They have a combined 181 years of consecutive payout increases.
Price targets on Johnson & Johnson have been moving higher, with bullish analysts now citing a range from about US$260 to US$305. This shift is closely linked to recent Street commentary that highlights solid execution in new medicines and MedTech, along with reduced legal uncertainty around talc litigation. As you read on, you will see how these changing targets fit into the broader analyst narrative and what to watch to stay on top of the story. Stay updated as the Fair Value for Johnson &...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
